VEGF-A Inhibition Ameliorates Podocyte Apoptosis via Repression of Activating Protein 1 in Diabetes

Abstract

Background/Aims: Vascular endothelial growth factor-A (VEGF-A) upregulation and podocyte apoptosis have been documented in diabetes. This study was designed to investigate whether inhibiting VEGF-A could ameliorate podocyte apoptosis in diabetes and the underlying mechanisms. Methods: In vitro, small interfering RNAs (siRNAs) of VEGF-A and activator protein 1 (AP-1, c-fos and c-jun), bevacizumab (VEGF-A inhibitor) and SP600125 (AP-1 inhibitor) were added to high glucose (30 m<smlcap>M</smlcap>) induced podocytes. Luciferase reporter assay was used to investigate whether AP-1 was a direct target of VEGF-A. In vivo, bevacizumab and SP600125 were administered to 12-week-old streptozotocin-induced male Sprague Dawley rats. The level of VEGF-A, c-fos, c-jun and bcl-2 were examined using immunostaining and Western blot analysis. Podocyte apoptosis was detected using the terminal deoxynucleotidyl transferase-mediated uridine 5′-triphosphate-biotin nick end labeling (TUNEL) assay, electron microscopy and flow cytometry. Results: Silencing VEGF-A or AP-1 upregulated bcl-2 and ameliorated podocyte apoptosis. Silencing VEGF-A decreased the level of c-fos and c-jun and bevacizumab and SP600125 treatment attenuated podocyte apoptosis. Luciferase reporter activity of VEGF-A-3′-UTR constructs was significantly provoked when stimulated with TGF-β1. In diabetic rat kidneys, VEGF-A co-localized with bcl-2 in podocytes. With bevacizumab and SP600125 treatment, the level of VEGF-A and AP-1 decreased while bcl-2 increased. Podocyte apoptotic rate was reduced with condensed podocyte nuclei less frequently observed. The urine albumin excretion rate (UAER) and albumin/creatinine were improved. Conclusion: This study demonstrates VEGF-A inhibition ameliorates podocyte apoptosis by regulating AP-1 and bcl-2 signaling. AP-1 is a direct target of VEGF-A and a novel player in podocyte apoptosis.

MicroRNA-27a promotes podocyte injury via PPARγ-mediated β-catenin activation in diabetic nephropathy

“…Rat models of diabetes were induced with a single intraperitoneal injection of either streptozotocin (65 mg/kg; S0130; Sigma-Aldrich) in 0.1 M citrate buffer (pH 4.5) or 0.1 M citrate buffer according to the protocol described previously. 34, 50, 51 Rats with a blood glucose level over 16.7 mmol/l were considered diabetic and thus included in the study, followed by treatment with the intraperitoneal administration of miR-27ai or miR-27am (4 ng/mm 3 ) or the appropriate scrambled control RNAs every day till killing at week 12 of diabetes.…”

“…On each unstained membrane slide, 50–100 individual glomeruli were laser microdissected and collected using the PALM MicroBeam LCM system (Zeiss) for RNA and protein extraction as described previously. 50 …”

MicroRNA-27a promotes renal tubulointerstitial fibrosis via suppressing PPARγ pathway in diabetic nephropathy

“…Diabetes was induced with streptozotocin (65mg/kg; S0130; Sigma-Aldrich, St. Louis., MO) according to the protocol described previously [57, 58]. To investigate the effect of miR-27a on renal tubulointerstitial fibrosis, miR-27a inhibitor or mimics (4 ng/mm 3 ) was injected peritoneally to diabetic rats every day.…”

Modulation of vascular endothelial growth factor and mitogen‐activated protein kinase‐related pathway involved in extracorporeal shockwave therapy accelerate diabetic wound healing

“…Bevacizumab, sold under the trade name Avastin, is a medication used to treat a number of types of cancers by slow injection into a vein . Studies on effects of anti‐VEGF treatment have been performed using Avastin in diabetic rat model …”